Auris Medical Holding Ltd. (EARS)
Stock Price:
$1.08 USD
0.04 (3.85%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $1.07 -0.01 (-0.93%) Aug 7, 7:57 PM
Key Info
| Market Cap |
4.98M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-6.63M |
| Shares Out |
4.76M |
| EPS (ttm) |
-1.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$1.08 |
| Previous Close |
$1.04 |
| Change ($) |
0.04 |
| Change (%) |
3.85% |
| Day's Open |
1.03 |
| Day's Range |
1.00 - 1.08 |
| Day's Volume |
364,836 |
| 52-Week Range |
0.65 - 3.20 |
More Stats
| Market Cap |
4.98M |
| Enterprise Value |
3.59M |
| Earnings Date (est) |
Aug 13, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.76M |
| Float |
4.12M |
| EPS (basic) |
-2.28 |
| EPS (diluted) |
-1.33 |
| FCF / Share |
-4.51 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
37,586 |
| Short Ratio |
0.39 |
| Short % of Float |
0.78% |
| Beta |
0.55 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.69 |
| Revenue |
n/a |
| Operating Income |
-7.26M |
| Net Income |
-6.63M |
| Free Cash Flow |
-8.46M |
| Net Cash |
1.38M |
| Net Cash / Share |
0.30 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-47.50% |
| ROE |
-136.94% |
| ROIC |
402.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
15.7
Current: $1.08
High
15.7
Target: 15.67
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -7.26 | -11.47 | -25.39 | -30.22 | -30.88 | -22.19 | -14.62 | -4.61 |
| Net Income | -6.63 | -11.50 | -24.41 | -30.66 | -29.71 | -18.19 | -15.00 | -4.60 |
| Shares Outstanding | 1.87 | 0.24 | 0.17 | 0.17 | 0.15 | 0.15 | - | - |
| Earnings Per Share | -2.28 | -14.46 | -111.61 | -178.60 | -184.00 | -132.00 | -202.00 | -80.00 |
| Operating Cash Flow | -8.39 | -13.23 | -24.28 | -29.45 | -28.73 | -19.32 | -14.04 | -4.50 |
| Capital Expenditures | -0.06 | 0.07 | -0.01 | -0.24 | -0.08 | -0.11 | -0.11 | -0.13 |
| Free Cash Flow | -8.46 | -13.16 | -24.28 | -29.70 | -28.81 | -19.43 | -14.15 | -4.63 |
| Cash & Equivalents | 1.38 | 5.39 | 14.97 | 32.44 | 50.24 | 56.93 | 23.87 | 0.00 |
| Total Debt | - | 1.44 | 10.13 | 12.36 | - | - | 13.71 | - |
| Net Cash / Debt | 1.38 | 3.96 | 4.85 | 20.08 | 50.24 | 56.93 | 10.15 | 0.00 |
| Assets | 9.23 | 9.88 | 17.83 | 35.66 | 52.81 | 59.49 | 26.25 | - |
| Liabilities | 3.19 | 6.23 | 19.99 | 21.52 | 8.07 | 6.21 | 17.22 | - |
| Book Value | 6.04 | 3.65 | -2.16 | 14.14 | 44.74 | 53.28 | 9.03 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Auris Medical Holding Ltd. |
| Country |
Bermuda |
| Employees |
8 |
| CEO |
Thomas Meyer |
Stock Information
| Ticker Symbol |
EARS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: EARS |
| IPO Date |
August 6, 2014 |
Description
Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.